Abdel-Moneim, Adel <br/><br/>
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.  [electronic resource] 

 -  Digestive diseases and sciences  May 2018 
 - 1341-1347 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1573-2568 
<br/><br/><label>Standard No.: </label>10.1007/s10620-018-5005-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Retreatment<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Sofosbuvir--therapeutic use<br/>Sulfonamides<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Valine<br/>Young Adult